Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients 3 years ago [#item_full_content] Newron Announces Results of Explanatory Studies With Evenamide in Healthy Volunteers and Patients With SchizophreniaDateApril 1, 2021In relation toSimilar postNewron Initiates First Potentially Pivotal Study with Evenamide in Patients with SchizophreniaDateSeptember 6, 2021In relation toSimilar postNewron Pharmaceuticals: Commercialization Partner Meiji Seika Together with Eisai Announce the Approval of Safinamide for Parkinson’s Disease in JapanDateSeptember 20, 2019In relation toSimilar post
